Adaptimmune Therapeutics PLC (ADAP) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research cut shares of Adaptimmune Therapeutics PLC (NASDAQ:ADAP) from a buy rating to a hold rating in a research report sent to investors on Friday morning.

According to Zacks, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom. “

Several other research analysts also recently issued reports on ADAP. BidaskClub upgraded shares of Adaptimmune Therapeutics PLC from a sell rating to a hold rating in a report on Sunday, July 16th. ValuEngine upgraded shares of Adaptimmune Therapeutics PLC from a strong sell rating to a sell rating in a report on Thursday, July 20th. Leerink Swann reiterated an outperform rating and set a $15.00 price target on shares of Adaptimmune Therapeutics PLC in a report on Friday, September 8th. SunTrust Banks, Inc. reiterated a buy rating and set a $10.00 price target on shares of Adaptimmune Therapeutics PLC in a report on Thursday, October 12th. Finally, TheStreet upgraded shares of Adaptimmune Therapeutics PLC from a d rating to a c rating in a report on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of $11.58.

Adaptimmune Therapeutics PLC (ADAP) traded up $0.02 during midday trading on Friday, reaching $8.10. The company’s stock had a trading volume of 148,300 shares, compared to its average volume of 266,017. Adaptimmune Therapeutics PLC has a 12-month low of $3.76 and a 12-month high of $9.29.

ILLEGAL ACTIVITY NOTICE: “Adaptimmune Therapeutics PLC (ADAP) Lowered to “Hold” at Zacks Investment Research” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://ledgergazette.com/2017/11/13/adaptimmune-therapeutics-plc-adap-lowered-to-hold-at-zacks-investment-research.html.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Matrix Capital Management Company LP acquired a new stake in Adaptimmune Therapeutics PLC in the second quarter valued at $39,027,000. Baillie Gifford & Co. grew its holdings in Adaptimmune Therapeutics PLC by 4.2% during the 3rd quarter. Baillie Gifford & Co. now owns 1,379,304 shares of the biotechnology company’s stock worth $11,297,000 after acquiring an additional 55,996 shares during the period. Renaissance Technologies LLC grew its holdings in Adaptimmune Therapeutics PLC by 75.4% during the 1st quarter. Renaissance Technologies LLC now owns 780,800 shares of the biotechnology company’s stock worth $4,302,000 after acquiring an additional 335,700 shares during the period. Wellington Management Group LLP grew its holdings in Adaptimmune Therapeutics PLC by 17.4% during the 1st quarter. Wellington Management Group LLP now owns 608,633 shares of the biotechnology company’s stock worth $3,354,000 after acquiring an additional 90,110 shares during the period. Finally, Artal Group S.A. grew its holdings in Adaptimmune Therapeutics PLC by 66.7% during the 3rd quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $4,095,000 after acquiring an additional 200,000 shares during the period. Institutional investors and hedge funds own 68.12% of the company’s stock.

Adaptimmune Therapeutics PLC Company Profile

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. The Company has developed a platform that enables it to identify cancer targets, find and genetically engineer TCR, and produce TCR therapeutic candidates for administration to patients.

Receive News & Ratings for Adaptimmune Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply